Ondansetron and RAD-140 Interaction: Avoid | Peptide Database

Join others researching Doxepin — share findings, ask questions, and learn from real experiences Doxepin is a tricyclic compound with a remarkably dose-dependent pharmacological profile. At higher doses (75-300 mg), it functions as a traditional tricyclic antidepressant (TCA) with activity across multiple neurotransmitter systems. However, at ultra-low doses (3-6 mg), doxepin acts almost exclusively as a highly selective histamine H1 receptor antagonist, making it one of the most targeted sleep maintenance agents available. This ultra-low dose formulation was approved by the FDA in 2010 under the brand name Silenor specifically for the treatment of insomnia characterized by difficulty with sleep maintenance. The distinction between high-dose and ultra-low dose doxepin is critical: at 3-6 mg, the drug avoids the anticholinergic, noradrenergic, and serotonergic side effects that characterize tricyclic antidepressants, resulting in a remarkably clean side effect profile. For biohackers and those seeking a non-habit-forming sleep aid, ultra-low dose doxepin offers a compelling option -- it does not produce dependence, does not cause rebound insomnia upon discontinuation, and maintains efficacy with long-term use. Unlike benzodiazepines and Z-drugs, it carries no abuse potential and is not a scheduled substance. At ultra-low doses (3-6 mg), doxepin's mechanism of action is dominated by potent and selective antagonism of the histamine H1 receptor. Doxepin has one of the highest affinities for the H1 receptor of any known compound (Ki approximately 0.17 nM), which means that even at very low plasma concentrations, it effectively blocks histaminergic wakefulness signaling. The histamine system is a key component of the ascending arousal pathway -- histaminergic neurons in the tuberomammillary nucleus of the hypothalamus fire during wakefulness and become quiescent during sleep. By blocking H1 receptors, ultra-low dose doxepin reduces this wake-promoting signal, particularly during the latter half of the night when endogenous histamine levels naturally begin to rise, which is why it is especially effective for sleep maintenance insomnia. At these low doses, doxepin has negligible affinity for muscarinic, adrenergic, and serotonergic receptors, which explains the absence of anticholinergic side effects (dry mouth, constipation, urinary retention) and cardiovascular effects that plague higher-dose TCA use. At antidepressant doses (75-300 mg), doxepin additionally inhibits reuptake of serotonin and norepinephrine and blocks muscarinic, alpha-1 adrenergic, and 5-HT2 receptors, producing a much broader and less selective pharmacological profile.

Noopept's best-established effect is enhancement of memory consolidation and retrieval. Animal studies consistently demonstrate improved performance on spatial memory, passive avoidance, and novel object recognition tasks. Human studies in patients with mild cognitive impairment and organic brain disorders show improvements in memory scores and attentional capacity. Demonstrated neuroprotective activity in multiple models of neuronal injury including oxidative stress, amyloid-beta toxicity, and glutamate excitotoxicity. The upregulation of BDNF and NGF provides trophic support to vulnerable neuronal populations, which may slow or prevent neurodegeneration. Users commonly report improved clarity of thought and sustained attention. While less studied than memory effects, the modulation of glutamatergic signaling and downstream cholinergic enhancement likely contribute to improved attentional performance. Approved in Russia for cognitive deficits following traumatic brain injury. Clinical trials demonstrated improvements in memory, attention, and emotional stability in patients recovering from cerebral trauma. Approved for cognitive decline associated with cerebrovascular insufficiency. Patients with chronic cerebrovascular disease showed improvements in cognitive test scores and reduction in associated emotional disturbances including anxiety and irritability. Preclinical evidence suggests potential benefits through NGF/BDNF upregulation and inhibition of amyloid-beta aggregation and neurotoxicity. Not yet tested in rigorous clinical trials for Alzheimer's specifically, but the mechanistic rationale is strong. An anxiolytic effect has been observed in both animal models and human clinical use at standard nootropic doses. Unlike benzodiazepines, the anxiolytic effect does not come with sedation or cognitive impairment, making it a potentially useful secondary benefit.